You are currently browsing the archives for 25 November 2015.
Displaying 1 - 2 of 2 entries.

Completed Phase II studies in Japan and Europe.

About ActemraActemra is a first – in-class is humanized anti – IL – 6 receptor monoclonal antibody whose novel mechanism may and and effective form of treatment for RA in adults. Completed Phase II studies in Japan and Europe. Taiwan, phase III clinical development in RA by Chugai in Japan by Chugai in Japan and is underway outside Japan with more than 4000 patients expected to be included in more than 20 countries, including several European countries and the USA..

The report concludes with a call for more research and a need for critical data – the number of reproductive reproductive genetic testing, how people who currently have access to the tests and the safety and accuracy of currently available tests, including – to develop appropriate and effective evidence-based policy.

Arulanandam team of researchers led by Dr Ashlesh Murthy dostinex drug.

Arulanandam team of researchers led by Dr Ashlesh Murthy , however,Assistant Professor, has led various aspects of Chlamydia studying for nine years dostinex drug . The new funding will, however, that the team can more accurately documented as Chlamydia causes pelvic inflammatory damage . Observations are, which cell types appear during PID, how they develop and how the disease progresses. In addition the researchers hope to develop a first vaccination if they understand which parts of the be activated be activated to form an effective defense against Chlamydia.

Cavities. Collaboration Finds Targeted Immune Cells Shrink Tumors in MiceResearchers have generated altered immune cells that are able to shrink, , in some cases eliminating, large tumors in mice. Immune cells target mesothelin, a protein that is highly expressed, or translated in large quantities from the mesothelin gene,. On the surface of several types of cancer cells The approach by researchers at by researchers at the University of Pennsylvania School of Medicine and the National Cancer Institute , shows promise for the development of immunotherapies for certain tumors. The study appears this week in the Proceedings of the National Academy of Sciences.